# BMRN — BioMarin Pharmaceutical · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** BMRN  
**Sources:** 17  
**Published:** 2026-10-04  
**Canonical:** https://app.k3vl4r.com/research/deep-research-bmrn-biomarin-pharmaceutical-catalysts-narrative-risks-6060

---

## Snapshot (as of Oct 2, 2026)

BioMarin closed at **$57.18** on October 2, 2026, down 2.16% on the day, with after-hours trading at ~$57.34 [[8]](https://stockanalysis.com/stocks/bmrn/forecast/), [[9]](https://tickernerd.com/stock/bmrn-forecast/). The stock is roughly **18% below its 52-week high of ~$70.24 (set in August 2026)** and sits near its 52-week low, with a market capitalization of about **$11.1B** [[9]](https://tickernerd.com/stock/bmrn-forecast/). This follows a meaningful decline: the stock traded near $69 in late August, ~$67 in early September, and ~$57 by early October, with year-to-date returns turning negative from around +11% in early September to about -3.8% by early October [[1]](https://www.ad-hoc-news.de/boerse/news/nebenwerte/biomarin-pharmaceutical-stock-gains-on-ascendis-settlement-and-analyst/70049285), [[9]](https://tickernerd.com/stock/bmrn-forecast/).

## Recent Catalysts (last ~1–3 months)

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-bmrn-biomarin-pharmaceutical-catalysts-narrative-risks-6060 (free to sign up)._